Hematology Reports (Jun 2015)

Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission

  • Hiroto Kaneko,
  • Yasuhiko Tsutsumi,
  • Takahiro Fujino,
  • Saeko Kuwahara,
  • Muneo Ohshiro,
  • Toshiki Iwai,
  • Junya Kuroda,
  • Shouhei Yokota,
  • Shigeo Horiike,
  • Masafumi Taniwaki

DOI
https://doi.org/10.4081/hr.2015.5812
Journal volume & issue
Vol. 7, no. 2

Abstract

Read online

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been applied to patients with diffuse large B-cell lymphoma (DLBCL); it is well established that ASCT shows significant survival benefits for chemosensitive relapse. However, half of relapsed patients are resistant to salvage chemotherapy, indicating that they are not suitable for ASCT. We retrospectively analyzed the clinical records of 47 patients with DLBCL classified as high or high-intermediate (higher) risk, according to the International Prognostic Index, who underwent upfront ASCT in first complete remission (CR1). Compared with 10 patients with similar characteristics who did not receive ASCT, event free survival at 5-year was significantly superior in ASCT group. Toxicity of ASCT was acceptable and therapy-related death was not observed. We therefore propose that upfront ASCT for higher risk DLBCL in CR1 might provide survival benefit, probably because the high-dose therapy removes minimally resided tumor.

Keywords